Andere Sprachen Immutep Limited

Aktien

A2H81H

AU000000IMM6

IMM

Markt geschlossen - Australian S.E. Andere Börsenplätze 08:10:43 01.05.2024			% 5 Tage	% 1. Jan.
0.42 ^AUD	-2.33%		+9.09%	+21.74%

30.04.	IMMUTEP LIMITED : Bewertung von Canaccord Genuity kaufen	ZM
24.04.	Immutep zeigt positive Daten in Studie zur Behandlung von Plattenepithelkarzinomen in Kopf und Hals	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immutep Quarterly Activities Report Q3 FY24	29.04.
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	24.04.
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24.04.
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18.04.
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18.04.
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18.04.
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18.04.
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18.04.
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17.04.
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17.04.
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17.04.
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17.04.
Immutep : Corporate Presentation	26.03.
Encouraging results for Immutep's cancer therapies	25.03.
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06.03.
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	05.03.
Immutep Announces First Clinical Data from 90mg Dosing of Efti	05.03.
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	05.03.
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	28.02.
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immutep Limited

Aktien

A2H81H

AU000000IMM6

IMM

Andere Sprachen

Filter